Newsbenzinga
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
· Published
Article summary
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
An excerpt from the original article.
Comments —
Loading comments…